Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.24 CAD 3.43% Market Closed
Market Cap: 309.1m CAD

Profound Medical Corp
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Profound Medical Corp
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
EPS (Diluted)
-$1
CAGR 3-Years
3%
CAGR 5-Years
-6%
CAGR 10-Years
9%
Titan Medical Inc
TSX:TMD
EPS (Diluted)
$0
CAGR 3-Years
53%
CAGR 5-Years
54%
CAGR 10-Years
37%
Theralase Technologies Inc
XTSX:TLT
EPS (Diluted)
CA$0
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
9%
MedMira Inc
XTSX:MIR
EPS (Diluted)
CA$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
0%
O
Ondine Biomedical Inc
LSE:OBI
EPS (Diluted)
CA$0
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Conavi Medical Corp
XTSX:CNVI
EPS (Diluted)
$0
CAGR 3-Years
-11%
CAGR 5-Years
-63%
CAGR 10-Years
28%
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
309.2m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
HIDDEN
Show

See Also

What is Profound Medical Corp's EPS (Diluted)?
EPS (Diluted)
-1.3 USD

Based on the financial report for Sep 30, 2025, Profound Medical Corp's EPS (Diluted) amounts to -1.3 USD.

What is Profound Medical Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
9%

Over the last year, the EPS (Diluted) growth was -2%. The average annual EPS (Diluted) growth rates for Profound Medical Corp have been 3% over the past three years , -6% over the past five years , and 9% over the past ten years .

Back to Top